Vargeese Chandra 4
4 · Wave Life Sciences Ltd. · Filed Feb 11, 2026
Research Summary
AI-generated summary of this filing
Wave Life (WVE) CTO Vargeese Chandra Receives RSU Awards
What Happened
Vargeese Chandra, Chief Technology Officer and Head of Platform Discovery Sciences at Wave Life Sciences (WVE), received equity awards reported on Feb 5, 2026 and completed a small open-market sale on Feb 9, 2026. The filing shows two awards: 45,625 restricted share units (RSUs) granted (no purchase price) and a derivative award of 273,750 shares (no purchase price), for a total of 319,375 award shares. Separately, Chandra sold 3,228 ordinary shares on Feb 9, 2026 at $13.45 per share for proceeds of $43,417; that sale was made solely to cover tax withholding tied to RSUs that vested on Feb 8, 2026.
Key Details
- Transaction dates & prices:
- Feb 5, 2026: Grant of 45,625 RSUs (acquired at $0.00).
- Feb 5, 2026: Grant of 273,750 derivative awards (acquired at $0.00).
- Feb 9, 2026: Sale of 3,228 shares at $13.45 for $43,417.
- Shares owned after transaction: Not specified in the Form 4 filing.
- Notable footnotes:
- F1: The 45,625 RSUs vest in four equal annual installments (25% each) on Feb 8, 2027–2030.
- F4: The derivative award vests 25% on Feb 8, 2027 and 6.25% quarterly thereafter through Feb 8, 2030.
- F3: The Feb 9 sale was an automatic sell-to-cover to satisfy tax withholding on RSUs that vested Feb 8, 2026.
- F2: Filing notes 3,162 ordinary shares were previously acquired via the 2019 ESPP (Jul 15, 2025 and Jan 14, 2026).
- Filing timeliness: Form 4 was filed Feb 11, 2026. Because Form 4s are generally due within two business days of a reportable transaction, the Feb 5 grants appear to have been reported after that two-business-day window (due Feb 9), while the Feb 9 sale was filed on the same day it was due.
Context
- The large items reported on Feb 5 are compensation awards (RSUs and a derivative award with scheduled vesting)—these are standard employee compensation and do not necessarily signal a purchase-based bullish bet.
- The Feb 9 sale was a routine automatic sale to cover tax withholding on vested RSUs (a common administrative transaction), not an independent investment decision to reduce holdings.
- Vesting schedules mean the awarded shares/options will become exercisable or convert to stock over multiple future dates rather than immediately.
Insider Transaction Report
- Award
Ordinary Shares
[F1][F2]2026-02-05+45,625→ 411,474 total - Sale
Ordinary Shares
[F3]2026-02-09$13.45/sh−3,228$43,417→ 408,246 total - Award
Share Option (right to buy)
[F4]2026-02-05+273,750→ 273,750 totalExercise: $12.75Exp: 2036-02-05→ Ordinary Shares (273,750 underlying)
Footnotes (4)
- [F1]Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030.
- [F2]Includes 3,162 ordinary shares acquired on July 15, 2025, and January 14, 2026, under the issuer's 2019 Employee Share Purchase Plan.
- [F3]On February 9, 2026, the reporting person sold 3,228 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.
- [F4]The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030.